Our Vision

To develop protein therapeutics to provide patients a better future.

Enabled by our proprietary protein production platform, Pfenex Expression Technology®, we are developing next generation and novel protein therapeutics to meaningfully improve existing treatment paradigms and create novel therapies for biological targets linked to critical diseases still waiting to successfully be addressed.

We have extensive experience in protein therapeutic development and a proven platform that enables deliberate and rapid candidate selection, fast drug development and potentially higher success rates for a wide range of complex modalities.

We aim to leverage existing drug development successes into a diversified pipeline consisting of multiple assets, including FDA-approved, next generation and novel biopharmaceutical products.

Our Heritage

Validated

A regulatory and clinically validated platform with FDA-approved PF708 (teriparatide injection) and with multiple partners’ programs nearing commercialization (Jazz, Merck and SIIPL)​.

Versatile

90-100% success in achieving high quality titer for Fabs, engineered antibody derivatives, non-antibody binding modalities and vaccine antigens. Deep institutional knowledge in >170 “lead” protein classes, including difficult to produce proteins which failed to express in E. coli, yeast and mammalian cell culture.

Experienced

Years of deep institutional knowledge derived from 60+ collaborations with biopharmaceutical companies, including a majority of the top 15 pharmaceutical companies with deep experience in recombinant protein production.

Management Team

Eef Schimmelpennink

Eef Schimmelpennink

Chief Executive Officer, President and Secretary

Evert B. Schimmelpennink has served as our Chief Executive Officer, President and Secretary since August 2017 and as our Chief Financial Officer since November 2019. Prior to his appointment, Mr. Schimmelpennink served as the Chief Executive Officer of Alvotech, a biosimilar development company from 2015 to July 2017. From September 2015 to November 2015, Mr. Schimmelpennink served as Vice President – Global Sterile Injectables of Pfizer Inc., a pharmaceutical company. Prior to that, Mr. Schimmelpennink served as Vice President—Global Generics from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA & Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc., a pharmaceutical company. From 2002 to 2011, Mr. Schimmelpennink held various roles at Synthon BV, a generics medicine company, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002 he held various roles with Numico NV, a Dutch maker of baby foods and nutritional bars and shakes, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr. Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. Mr. Schimmelpennink received a master’s in bioprocess engineering from the Wageningen University in the Netherlands.

Martin Brenner

Martin Brenner

Chief Scientific Officer

Dr. Martin B. Brenner has served as our Senior Vice President, Chief Scientific Officer since March 2019. From 2017 to 2018, Dr. Brenner served as Chief Scientific Officer at Recursion Pharmaceuticals, Inc., a biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Laboratories of Merck & Co., Inc., a pharmaceutical company. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca PLC, a pharmaceutical company. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer Inc., a pharmaceutical company. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Eli Lilly and Company, a pharmaceutical company. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany and a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.

Shawn Scranton

Shawn Scranton

Chief Operating Officer

Dr. Shawn A. Scranton has served as our Senior Vice President, Chief Operating Officer since October 2018. He previously served as Chief Scientific Consultant for Sentynl Therapeutics, Inc. a wholly owned subsidiarity of Zydus-Cadila, a pharmaceutical company, from 2017 to 2018. From 2015 to 2017, Dr. Scranton served as Senior Vice President, Chief Scientific Officer at Sentynl Therapeutics, Inc., a pharmaceutical company. Prior to Sentynl, Dr. Scranton served as Consultant, Managing Director at Strategic Therapeutic Solutions, LLC, a pharmaceutical consulting company, and from 2007 to 2012, Dr. Scranton served as VP, Scientific Operations at Victory Pharma, Inc., a specialty pharmaceutical company. Dr. Scranton served as Sr. Director of Translational Medicine at Kalypsys, Inc., a pharmaceutical company, from 2005 to 2007, and as Director of Clinical Research/Program Director at Salmedix Corporation, a drug development company, from 2001 to 2005. From 1998 to 2000, Dr. Scranton served as Senior Clinical Research Scientist, Clinical Development at Dura Pharmaceuticals, Inc., a pharmaceutical company. Dr. Scranton holds a Doctor of Pharmacy from the University of the Pacific School of Pharmacy (1994) and a B.A. in Animal Physiology from the University of California, San Diego (1988).

Patrick K. Lucy

Patrick K. Lucy

Chief Business Officer

Patrick K. Lucy has served as our Senior Vice President, Chief Business Officer since 2014. Mr. Lucy also served as our Interim Chief Executive Officer, President and Secretary from January 2017 to August 2017, when Mr. Schimmelpennink was appointed to those roles. Mr. Lucy previously served as our Vice President of Business Development and Marketing between 2009 and 2014. Prior to joining us, Mr. Lucy held the position of Director of Business Development at DowPharma, a business within The Dow Chemical Company, a chemicals manufacturer, from 2002 to 2009. From 1999 to 2002, he held the position of Director of Business Development at Collaborative BioAlliance, Inc., a biotechnology company, which was acquired by The Dow Chemical Company. From 1998 to 1999, Mr. Lucy worked as a Validation Manager and Capital Project Manager and from 1996 to 1998, as a Quality Control Biochemistry Supervisor at Lonza Biologics Inc., a chemicals and biotechnology company. From 1991 to 1996, Mr. Lucy held various positions at Repligen Corporation, a life sciences company. Mr. Lucy currently serves on the Scientific Advisory Board of Explorations in Global Health (ExGloH) a division within the Leidos Health Group. Mr. Lucy holds a bachelor’s degree in Biology from Villanova University.